Pfizer kicks off PhIII programme for haemophilia B gene therapy
Pfizer has kicked off a late-stage trial assessing efficacy and safety of the investigational gene therapy fidanacogene elaparvovec for the treatment of haemophilia B.
17th July 2018
Latest news
UK panel says human embryo editing ‘morally permissible’
An independent ethics panel in the UK has concluded that genome editing to influence the characteristics of a future person could be “morally permissible”.
17th July 2018
NICE issues cerebral palsy guideline for adults
The National Institute for Health and Care Excellence has published a new guideline that aims to address current variation in the provision of services for adults with cerebral palsy.
17th July 2018
EU approval for Akcea/Ionis’ rare disease therapy
European regulators have approved Akcea and Ionis’ Tegsedi for patients with hereditary transthyretin amyloidosis (hATTR), a rare disease causing build up of amyloid in the peripheral nervous system and multiple organs.
17th July 2018
Enter now and showcase your talents industry-wide
The all new Sales Awards offers a unique opportunity for sales professionals at all levels of their career to sharpen their skills and showcase their talents industry-wide.
16th July 2018
With just 6 weeks to go spaces are filling up fast - reserve your place now to avoid missing out
The PharmaTimes Marketer of the Year competition offers a unique opportunity for all marketers, from aspiring to experienced, to sharpen their skills and showcase their talents against marketing professionals, industry-wide.
16th July 2018
Sobi launches Kineret for AOSD, SJIA
Sobi UK and Ireland has announced the launch of Kineret across the country offering a new treatment option for Adult Onset Stills Disease (AOSD) and Systemic-Onset Juvenile Idiopathic Arthritis (SJIA).
16th July 2018
NICE backs AZ’ asthma biologic Fasenra
AstraZeneca’s biologic Fasenra will likely be funded on the NHS as a treatment for people with severe eosinophilic asthma.
16th July 2018
FDA approves first smallpox therapy
US regulators have approved the first treatment designed to mitigate the impact of a potential outbreak of smallpox caused by bioterrorism.
16th July 2018
UCB, Amgen refile osteoporosis drug Evenity
UCB and Amgen have brought their bone-boosting drug Evenity back to US regulators for review, following an initial rejection in July last year.
16th July 2018
Put your agency in the spotlight, ENTER NOW
“The ‘NHS Challenge’ is designed specifically for agencies that have strong experience in dealing with UK specific challenges,” says the executive steering group's Eric Hansen.
13th July 2018
Recognising the outstanding achievements of medical and scientific professionals
PharmaTimes Media has announced the Medical & Scientific Excellence Awards as the latest addition to its highly prestigious portfolio of events - and now is the time to enter!
13th July 2018
Brexit ambition is ‘fine’ but execution is key, says Brexit Health Alliance
"There is always a danger that health issues are not kept to the fore" in negotiations, says Niall Dickson
13th July 2018
NICE turns down Darzalex combo for pre-treated multiple myeloma
Janssen says it is disappointed that NHS cost regulators are not backing NHS use of Darzalez (daratumumab) plus bortezomib and dexamethasone (DBd) for previously treated multiple myeloma in adults.
12th July 2018
GSK sells psoriasis/dermatitis therapy to Dermavant
GlaxoSmithKline has sold rights to an experimental therapy being developed for psoriasis and dermatitis to Dermavant in a deal worth $330 million.
12th July 2018
